Cancer Immunology Reserch

Hyperthermic intrathoracic chemotherapy modulates the immune microenvironment of pleural mesothelioma and improves the impact of dual immune checkpoint inhibition

by

Cancer Immunol Res. 2024 Nov 25. doi: 10.1158/2326-6066.CIR-24-0245. Online ahead of print. ABSTRACT Pleural mesothelioma (PM) is a fatal disease with limited treatment options. Recently, PM management has improved with the development of immune checkpoint inhibitors (ICIs). In first-line therapy, dual PD-1 and CTLA-4 blockade enhances tumor control and patient survival compared with chemotherapy. Unfortunately, … Read more

CD49a targeting enhances NK cell function and antitumor immunity

by

Cancer Immunol Res. 2024 Nov 21. doi: 10.1158/2326-6066.CIR-24-0124. Online ahead of print. ABSTRACT Approximately 70% of patients receiving immune checkpoint blockade therapies develop treatment resistance. Thus, there is a need for the identification of additional immunotherapeutic targets. CD49a is a membrane protein expressed on NK cells and T cells. In this study, we found that … Read more

A PSMA-targeted Tri-specific Killer Engager enhances NK cell cytotoxicity against prostate cancer

by

Cancer Immunol Res. 2024 Nov 15. doi: 10.1158/2326-6066.CIR-24-0273. Online ahead of print. ABSTRACT Natural killer (NK) cell tumor infiltration is associated with good prognosis in patients with metastatic castration-resistant prostate cancer (mCRPC). NK cells recognize and kill targets by a process called natural cytotoxicity. We hypothesized that promoting an antigen-specific synapse with co-activation may enhance … Read more

Combination CXCR4 and PD1 blockade enhances intratumoral dendritic cell activation and immune responses against hepatocellular carcinoma

by

Cancer Immunol Res. 2024 Nov 8. doi: 10.1158/2326-6066.CIR-24-0324. Online ahead of print. ABSTRACT Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of unresectable hepatocellular carcinoma (HCC), but their impressive efficacy is seen in just a fraction of patients. One key mechanism of immunotherapy resistance is the paucity of dendritic cells (DCs) in liver malignancies. Here, … Read more

Targeting of tumoral NAC1 mitigates myeloid-derived suppressor cell-mediated immunosuppression and potentiates anti-PD-1 therapy in ovarian cancer

by

Cancer Immunol Res. 2024 Nov 12. doi: 10.1158/2326-6066.CIR-24-0084. Online ahead of print. ABSTRACT Epithelial ovarian cancer (EOC) is the most common type of ovarian cancer with a low rate of response to immunotherapy such as immune checkpoint blockade (ICB) therapy. Here, we report that nucleus accumbens-associated protein 1 (NAC1), a putative driver of EOC, has … Read more

Inflammatory stress determines the need for chemotherapy in patients with HER2-positive esophagogastric adenocarcinoma receiving targeted and immunotherapy

by

Cancer Immunol Res. 2024 Nov 11. doi: 10.1158/2326-6066.CIR-24-0561. Online ahead of print. ABSTRACT Anti-PD-1, trastuzumab, and chemotherapy are used in the treatment of patients with advanced HER2-positive esophagogastric adenocarcinoma (EGA), but long-term survival remains limited. Herein, we report extended follow-up data from the INTEGA trial (NCT03409848), which investigated the efficacy of the anti-PD-1 nivolumab, trastuzumab, … Read more

Alternate MHC I antigen presentation pathways allow CD8+ T-cell recognition and killing of cancer cells in the absence of ß2M or TAP

by

Cancer Immunol Res. 2024 Nov 1. doi: 10.1158/2326-6066.CIR-24-0320. Online ahead of print. ABSTRACT Major histocpmpatibilty complex class I (MHC I) antigen presentation allows CD8+ T cells to detect and eliminate cancerous or virally infected cells. The MHC I pathway is not essential for cell growth and viability and consequently cancers and viruses can evade control … Read more

BTN2A1: A Novel Target to Boost Tumor Killing Capacity of Human γδ T Cells

by

Cancer Immunol Res. 2024 Oct 30:OF1. doi: 10.1158/2326-6066.CIR-24-0925. Online ahead of print. ABSTRACT γδ T cells have recently raised great interest as effector cells in cancer immunotherapy because of their HLA-independent mode of action and their broad tumor reactivity. To translate the application of γδ T cells into clinically effective immunotherapies, specific tumor targeting and/or … Read more

Gefitinib Reverses PD-L1-Mediated Immunosuppression Induced by long-term Glutamine blockade in Bladder Cancer

by

Cancer Immunol Res. 2024 Oct 29. doi: 10.1158/2326-6066.CIR-24-0039. Online ahead of print. ABSTRACT Glutamine is a major energy source for tumor cells and blocking glutamine metabolism is being investigated as a promising strategy for cancer therapy. However, the antitumor effect of glutamine blockade in bladder cancer remains unclear, necessitating further investigation. Here, we demonstrated that … Read more

deneme bonusu veren siteler - canlı bahis siteleri - casino siteleri casino siteleri deneme bonusu veren siteler canlı casino siteleri